Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18638696 | 0.81 | — | — | |
| SCHEMBL21768332 | 0.78 | PIK3CD (0.30) | PIK3CD | |
| SCHEMBL2935124 | 0.77 | TSHR (0.47) | TDP1ALDH1A1TSHRMAPK1CYP2D6 | |
| SCHEMBL19072799 | 0.73 | SLC22A1 (0.37) | HTR2AHRH1TDP1ALDH1A1TSHR | |
| SCHEMBL22824372 | 0.73 | — | — | |
| SCHEMBL25721027 | 0.73 | ALDH1A1 (0.33) | ALDH1A1TSHRMAPK1 | |
| SCHEMBL8754497 | 0.73 | ALDH1A1 (0.33) | PIK3CDALDH1A1TSHRMAPK1 | |
| SCHEMBL13412952 | 0.73 | TSHR (0.33) | HTR2AHRH1ALDH1A1TSHRMAPK1 | |
| SCHEMBL19243166 | 0.73 | SLC22A1 (0.37) | HTR2AHRH1TDP1ALDH1A1TSHR | |
| SCHEMBL25038928 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11160758-B2 | Modified release formulations and uses thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2021-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11160758-B2 | Modified release formulations and uses thereof | SRI, ABCG2, SUCNR1 | HTR2A 357/4885HRH1 1162/4885TDP1 1956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.